BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/10/2023 7:29:15 AM | Browse: 169 | Download: 577
 |
Received |
|
2022-09-27 12:36 |
|
Peer-Review Started |
|
2022-09-27 12:38 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-01-03 21:14 |
|
Revised |
|
2023-01-08 07:43 |
|
Second Decision |
|
2023-02-21 04:15 |
|
Accepted by Journal Editor-in-Chief |
|
2023-02-21 10:40 |
|
Accepted by Company Editor-in-Chief |
|
2023-02-23 04:13 |
|
Articles in Press |
|
2023-02-23 04:13 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-03-01 04:18 |
|
Typeset the Manuscript |
|
2023-03-06 02:58 |
|
Publish the Manuscript Online |
|
2023-03-10 07:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Systemic treatment for unresectable hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Tawithep Leowattana and PathompThep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, BMed, MD, MSc, PhD, Full Professor, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Rachatawee, Bangkok 10400, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Hepatocellular carcinoma; Unresectable hepatocellular carcinoma; Non-alcoholic fatty liver disease; Tyrosine kinase inhibitor; Sorafenib; Lenvatinib; Immune checkpoint inhibitor; Atezolizumab; Bevacizumab |
| Core Tip |
Hepatocellular carcinoma (HCC) is a major health problem that is the fourth leading cause of cancer-related mortality worldwide. The five-year survival rate was nearly 19%, but only 2% in metastatic HCC. The first oral multikinase inhibitor for the systemic treatment of advanced or unresectable HCC (uHCC) was sorafenib. However, when compared to sorafenib, the combination of atezolizumab and bevacizumab increased survival rates and was authorized as first-line treatment for uHCC. Regorafenib and cabozantinib are suggested for use as second-line drugs in the event that the disease progresses. Transarterial chemoembolization for palliative care or downstaging is also suggested. This review focused on systemic therapy for uHCC patients who are not appropriate for liver-directed therapy. |
| Publish Date |
2023-03-10 07:29 |
| Citation |
Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1551-1568 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i10/1551.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i10.1551 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
